Literature DB >> 17119927

Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone.

Hye Sook Ahn1, Sung Eun Kim, Hyun-Jong Jang, Myung-Jun Kim, Duck-Joo Rhie, Shin-Hee Yoon, Yang-Hyeok Jo, Myung-Suk Kim, Ki-Wug Sung, Seong Yun Kim, Sang June Hahn.   

Abstract

The effects of rosiglitazone and troglitazone were examined on cloned Kv1.3 channels stably expressed in Chinese hamster ovary cells using the whole-cell configuration of the patch-clamp technique. Rosiglitazone decreased the Kv1.3 currents and accelerated the decay rate of current inactivation in a concentration-dependent manner with an IC(50) of 18.6 microM. These effects were reversible after washout of the drug. Troglitazone caused the block of Kv1.3 with a similar pattern but was five times more potent than rosiglitazone with an IC(50) of 3.5 microM. The block of Kv1.3 by rosiglitazone and troglitazone was voltage-dependent at a membrane potential coinciding with the activation of the channels. Both drugs decreased the tail current amplitude and slowed the deactivation process of Kv1.3, resulting in a tail crossover phenomenon. These results indicate that rosiglitazone and troglitazone block the open state of Kv1.3 channels, suggesting that it is an important pharmacological target for rosiglitazone as a potent blocker of Kv1.3 channels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119927     DOI: 10.1007/s00210-006-0118-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  19 in total

1.  The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity.

Authors:  Jianchao Xu; Peili Wang; Yanyan Li; Guoyong Li; Leonard K Kaczmarek; Yanling Wu; Pandelakis A Koni; Richard A Flavell; Gary V Desir
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

2.  Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.

Authors:  K Eto; Y Ohya; Y Nakamura; I Abe; M Fujishima
Journal:  Eur J Pharmacol       Date:  2001-06-29       Impact factor: 4.432

3.  Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

Authors:  I Barroso; M Gurnell; V E Crowley; M Agostini; J W Schwabe; M A Soos; G L Maslen; T D Williams; H Lewis; A J Schafer; V K Chatterjee; S O'Rahilly
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

4.  Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes.

Authors:  G A Knock; S K Mishra; P I Aaronson
Journal:  Eur J Pharmacol       Date:  1999-02-26       Impact factor: 4.432

5.  The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

Authors:  T M Willson; J E Cobb; D J Cowan; R W Wiethe; I D Correa; S R Prakash; K D Beck; L B Moore; S A Kliewer; J M Lehmann
Journal:  J Med Chem       Date:  1996-02-02       Impact factor: 7.446

6.  Class III antiarrhythmic effects of zatebradine. Time-, state-, use-, and voltage-dependent block of hKv1.5 channels.

Authors:  C Valenzuela; E Delpón; L Franqueza; P Gay; O Pérez; J Tamargo; D J Snyders
Journal:  Circulation       Date:  1996-08-01       Impact factor: 29.690

7.  Voltage-gated potassium channel Kv1.3 regulates GLUT4 trafficking to the plasma membrane via a Ca2+-dependent mechanism.

Authors:  Yanyan Li; Peili Wang; Jianchao Xu; Gary V Desir
Journal:  Am J Physiol Cell Physiol       Date:  2006-02       Impact factor: 4.249

8.  Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach.

Authors:  T Izumi; S Enomoto; K Hosiyama; K Sasahara; A Shibukawa; T Nakagawa; Y Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  1996-06       Impact factor: 4.030

9.  Determinants of antiarrhythmic drug action. Electrostatic and hydrophobic components of block of the human cardiac hKv1.5 channel.

Authors:  D J Snyders; S W Yeola
Journal:  Circ Res       Date:  1995-09       Impact factor: 17.367

10.  Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.

Authors:  J Berger; P Bailey; C Biswas; C A Cullinan; T W Doebber; N S Hayes; R Saperstein; R G Smith; M D Leibowitz
Journal:  Endocrinology       Date:  1996-10       Impact factor: 4.736

View more
  11 in total

1.  Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation.

Authors:  I Jeong; B H Choi; S J Hahn
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

2.  Open channel block of Kv1.5 currents by citalopram.

Authors:  Hyang Mi Lee; Sang June Hahn; Bok Hee Choi
Journal:  Acta Pharmacol Sin       Date:  2010-03-15       Impact factor: 6.150

3.  Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels.

Authors:  Yasser Majeed; Yahya Bahnasi; Victoria A L Seymour; Lesley A Wilson; Carol J Milligan; Anil K Agarwal; Piruthivi Sukumar; Jacqueline Naylor; David J Beech
Journal:  Mol Pharmacol       Date:  2011-03-15       Impact factor: 4.436

Review 4.  Kv1.3: a potential pharmacological target for diabetes.

Authors:  Bok Hee Choi; Sang June Hahn
Journal:  Acta Pharmacol Sin       Date:  2010-08-16       Impact factor: 6.150

5.  Effects of rosiglitazone on altered electrical left ventricular papillary muscle activities of diabetic rat.

Authors:  Servet Kavak; Mustafa Emre; Tamer Tetiker; Tuyana Kavak; Zekeriya Kolcu; Ismail Günay
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-21       Impact factor: 3.000

6.  Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery.

Authors:  Radda Rusinova; Karl F Herold; R Lea Sanford; Denise V Greathouse; Hugh C Hemmings; Olaf S Andersen
Journal:  J Gen Physiol       Date:  2011-08       Impact factor: 4.086

7.  Impaired firing properties of dentate granule neurons in an Alzheimer's disease animal model are rescued by PPARγ agonism.

Authors:  Miroslav N Nenov; Filippo Tempia; Larry Denner; Kelly T Dineley; Fernanda Laezza
Journal:  J Neurophysiol       Date:  2014-12-24       Impact factor: 2.714

8.  Potent suppression of Kv1.3 potassium channel and IL-2 secretion by diphenyl phosphine oxide-1 in human T cells.

Authors:  Ning Zhao; Qian Dong; Li-Li Du; Xiao-Xing Fu; Yi-Mei Du; Yu-Hua Liao
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

9.  Arylbenzazepines are potent modulators for the delayed rectifier K+ channel: a potential mechanism for their neuroprotective effects.

Authors:  Xue-Qin Chen; Jing Zhang; John L Neumeyer; Guo-Zhang Jin; Guo-Yuan Hu; Ao Zhang; Xuechu Zhen
Journal:  PLoS One       Date:  2009-06-05       Impact factor: 3.240

10.  Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties.

Authors:  Ning Zhao; Qian Dong; Cheng Qian; Sen Li; Qiong-Feng Wu; Dan Ding; Jing Li; Bin-Bin Wang; Ke-fang Guo; Jiang-jiao Xie; Xiang Cheng; Yu-Hua Liao; Yi-Mei Du
Journal:  Sci Rep       Date:  2015-11-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.